| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000028539 |
| Receipt No. | R000032654 |
| Official scientific title of the study | A study for evaluating the effects of oral intake of food containing lactic acid bacteria on intestinal environment. A placebo-controlled, randomized, double-blind, cross-over trial. |
| Date of disclosure of the study information | 2017/08/04 |
| Last modified on | 2018/04/27 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | A study for evaluating the effects of oral intake of food containing lactic acid bacteria on intestinal environment. A placebo-controlled, randomized, double-blind, cross-over trial. | |
| Title of the study (Brief title) | A study for evaluating the effects of oral intake of food containing lactic acid bacteria on intestinal environment. | |
| Region |
|
|
| Condition | |||
| Condition | Subjects with a tendency for constipation | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the effects of food containing lactic acid bacteria(Lactobacillus brevis) on intestinal environment of subjects with a tendency for constipation. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Number of Lactobacillus genus in feces, number of Bifidobacterium genus in feces, acetic acid content in feces |
| Key secondary outcomes | Organic acids content in feces, analysis of gut microbiota, diversity of gut microbiota, metagenomic analysis of functional profile of gut microbiota community, ammonia content in feces, decay product content in feces, pH and water content in feces, questionnaire(Defecation days, defecation frequency, fecal amount fecal shape, fecal color, fecal odor, feeling after defecation) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Food containing lactic acid bacteria (2 weeks intake) - washout period (2 weeks) - placebo (not containing lactic acid bacteria) (2 weeks intake) | |
| Interventions/Control_2 | Placebo (not containing lactic acid bacteria) (2 weeks intake) - washout period (2 weeks) - food containing lactic acid bacteria (2 weeks intake) | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Males and females from 20 to 64 years of age
(2) Subjects with a tendency for constipation at three to five times of defecation per week at the point of screening examination(2 weeks) (3) Subjects giving written informed consent |
|||
| Key exclusion criteria | (1) Individuals taking antiflatulents and/or laxatives (including purgative drug) in common use
(2) Individuals taking health foods in common use, which influence intestinal regulation at the point of screening examination (3) Individuals taking antibiotics and/or drugs which influence laxatives(including purgative drugs) in common use at the point of screening examination (4) Individuals who are not able to stop consumption of foods containing lactic acid bacteria, bifidobacteria, natto bacteria, oligosaccharides, dietary fibers, high amount of sugar alcohol and/or other health foods including food for specified health use and food with function claim, which influence intestinal regulation during the study period (5) Individuals presenting known food allergy (6) Individuals taking large amounts of alcohol on a daily basis (7) Individuals who are suffered from a disease which needs treatment urgently or individuals with severe complications (8) Individuals with a digestive organ disease or surgical history who has an influence on digestive absorption and defecation (9) Individuals who are judged to be unsuitable as a subject from an answer of a subjective background questionnaire (10) Individuals who are pregnant or breast-feeding, or have the will of pregnancy during the study period (11) Individuals who are under treatment or have a history of drug/alcohol dependence (12) Individuals who participate in other clinical studies or who are in willing to participate to these studies using foods, drugs and/or cosmetics (13) Individuals who are judged as unsuitable for the study by the investigator for the other reasons |
|||
| Target sample size | 22 | |||
| Research contact person | |
| Name of lead principal investigator | Yoshitaka Iwama |
| Organization | Nihonbashi Cardiology Clinic |
| Division name | Director |
| Address | 13-4 Nihonbashi Kodenma-cho Chuo-ku Tokyo-to |
| TEL | 03-5641-4133 |
| yiwama@well-sleep.jp | |
| Public contact | |
| Name of contact person | Eiji Yoshikawa |
| Organization | KSO Corporation |
| Division name | Sales department |
| Address | 1-9-7 Shibaura, Minato-ku, Tokyo |
| TEL | 03-3452-7733 |
| Homepage URL | |
| yoshikawa@kso.co.jp | |
| Sponsor | |
| Institute | KSO Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Lotte Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | http://lifescience.co.jp/yk/yk18/ykj1804.html |
| Results | Jpn Pharmacol Ther 2018 46(4)549-60 |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032654 |